The CB2 agonist JWH-015 has no effect on ERK1/2 or pERK1/2 immunoreactivity in HT22 cells. A brief 60 minute treatment of HT22 cells with the CB2 agonist JWH-015 fails to significantly increase ERK1/2 immunoreactivity (A) or pERK1/2 immunoreactivity (B). In the ERK1/2 immunofluorescence experiment, n equals 54 and 59 cells for vehicle and JWH-015 treatments, respectively. In the pERK1/2 immunofluorescence experiment, n equals 34 and 40 cells for vehicle and JWH-015 treatments, respectively. Significance was determined by a two-sample t-test.